mRNA Vaccine and Therapeutics Market

Market Size

The global mRNA vaccine and therapeutics market, valued at USD 9 million in 2026, is projected to reach USD 17,036 million by 2035, representing a high CAGR during the forecast period 2026 to 2035.

Market Report: Key Takeaways

• The historical growth for mRNA vaccine and therapeutics is attributed to the surge in COVID-19. Post COVID-19, the increasing prevalence of oncological disorders and infectious diseases have amplified the demand for mRNA vaccines and therapeutics. 
• In terms of target disease indication, respiratory syncytial virus infection (RSV) is likely to capture majority of the revenue share. 
• In terms of geographical regions, North America holds 75% of the market share due to the increase in research related to vaccines and drugs, favorable regulatory guidelines for approval of mRNA vaccines and therapeutics, and a strong presence of key mRNA developers.

Market Overview

Messenger ribonucleic acid (mRNA) technology has revolutionized protein synthesis by carrying genetic instructions from DNA to ribosomes in a single-stranded RNA form. Using mRNA technologies has transformed the global biomedical landscape, offering new therapeutic opportunities for diseases once considered untreatable. As a result, mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches.

Following the onset of the COVID-19 pandemic, the global mRNA vaccine & therapeutics market has gained unprecedented momentum. The success of mRNA-based COVID-19 vaccines not only showcased the rapid adaptability of this technology but also accelerated research and investment across numerous therapeutic domains. However, with COVID-19 largely suppressed, the market has experienced a temporary decline. As per our mRNA vaccine and therapeutics market forecast, it is projected to rebound strongly post-2029 fueled by expanding non-COVID indications such as oncology, rare diseases, and infectious diseases beyond COVID-19.

Within this expanding ecosystem, mRNA cancer vaccines and therapeutics market has seen remarkable advancements as increasing number of oncology patients receive targeted, immune-based interventions tailored through mRNA platforms. Oncological disorders currently capture around 25% of the mRNA vaccine and therapeutics market share, highlighting the shift toward immune-focused, targeted cancer treatments.

Presently, there are five mRNA vaccines providers that have successfully secured market approval for their mRNA vaccines, marking a crucial milestone in the advancement and commercialization of these vaccines targeting various diseases. This is further supported by the fact that many mRNA vaccine and therapeutic candidates have progressed to Phase III clinical trials, demonstrating strong patient enrollment and robust clinical evaluation.

The growing pipeline of mRNA developers is also driving growth in the mRNA synthesis and manufacturing market, as they are seeking contract services to scale-up the pharmaceutical manufacturing process of mRNA vaccines and therapeutics.

Market Trends

• Partnerships and Collaborations: The mRNA vaccines and therapeutics market is witnessing a rise in partnership activity. For instance, Moderna and BioNTech signed an agreement to expand the development of mRNA vaccines and therapeutics. Likewise, several other market players are entering into collaborations for expanding research and clinical trial activity.
• Funding and Investment Analysis: mRNA developers such as Moderna (US-based) and Curevac (Germany-based) have secured multi-million-dollar investments to advance research and commercialize mRNA vaccines and therapeutics.
• Clinical Trial Analysis: The mRNA vaccines and therapeutics market analysis suggests that this market is rapidly growing with over 20% of the vaccines and therapeutics in phase III clinical trials, demonstrating significant progress in clinical validation. Around 70% of the market share is utilized by various pharmaceutical industry players, with Moderna (US-based) leading in the number of ongoing clinical trials, followed closely by BioNTech (Germany-based).
• Patent Analysis: The mRNA vaccines & therapeutics market is experiencing a robust upward trend in patent activity, with over 1,060 patents filed or granted globally and a surge in new applications, reflecting accelerated innovation post-2020. Rising mRNA patents are primarily driven by platform-based versatility and broad commercial potential across infectious diseases, oncology, and other indications, which incentivize mRNA companies to secure and defend differentiated delivery and formulation technologies.
• Big Pharma Analysis: Big pharmaceutical companies, such as Pfizer, Sanofi and Bayer have partnered with smaller, dedicated mRNA-based therapeutic and vaccines developers to expand their respective capabilities in this field. Pfizer has undertaken the maximum initiatives, followed by Sanofi (like translate bio acquisition to accelerate its efforts in developing transformative vaccines and therapies using mRNA technologies) primarily due to their pioneering roles in COVID-19 vaccine development and ongoing expansions into next-generation applications.

Industry Experts on mRNA Vaccine and Therapeutics Market Growth

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Business Development Manager, Mid-sized Organization, Australia
• Senior Director Business Development, Large Organization, Belgium
• Team Leader, Large Organization, South Korea

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer, Large Organization, US
• President, Mid-sized Organization, Switzerland
• Medical Professional, Large-sized Organization, Germany
• Chief Executive Officer, Large-sized Organization, Italy
• Director of Advanced Drug Delivery, Mid-sized Organization, UK
• Co-founder, Large-sized Organization, Germany
• Chief Executive Officer, Mid-sized Organization, US
• Chief Executive Officer, Large Organization, US
• Deputy Director, Mid-sized Organization, US
• Co-founder and Chief Executive Officer, Mid-sized Organization, Germany

Market Segmentation Analysis

Non-COVID applications to be the future of mRNA Vaccines and Therapeutics Market

• Based on the application area, the global market is segmented into COVID-19 and non-COVID. According to the mRNA vaccine and therapeutics report, the COVID-19 segment captures the overall market share for the current year. This growth stems from the massive global demand, rising approvals, increasing need for regulatory compliance, and widespread deployment of mRNA-based COVID-19 vaccines.

• The non-COVID mRNA segment is expected to dominate the market in the coming years due to increased R&D investments, clinical advancements, and regulatory approvals for diverse applications like cancer immunotherapies, rare diseases, influenza, RSV, and genetic disorders, unlocking vast unexplored market.

mRNA Vaccine and Therapeutics Market: Scope of the Report

Market Segments

Based on our market research, we have segmented the mRNA vaccine and therapeutics market into various segments, such as distribution by application area, target disease indication and geographical regions

By Application Area

• COVID-19
• Non-COVID

By Type of Disease Indication

• RSV Infection
• Recurrent / Metastatic Head and Neck Cancer
• Influenza
• Non-Small Cell Lung Cancer
• Melanoma
• Muscle-Invasive Urothelial Carcinoma
• Norovirus Acute Gastroenteritis
• Propionic Acidemia
• Mononucleosis
• Cystic Fibrosis

By Geographical Regions

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Australia
  • South Korea
  • Japan

Frequently Asked Questions